Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Improving Margins ⢠Low Returns NVST offers strong liquidity and improving margins, but low annual returns, intangible-heavy assets, and demanding earnings multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Mild downtrend ⢠Support rebound ⢠Resistance capped Support Level: $26.64 Resistance Level: $27.80â$28.10 NVST remains mildly bearish over the last month, with support at $26.64 and resistance at $27.80â$28.10; watch for a breakout above resistance or a breakdown below support.
Sentiment & News
Key News Insights: ⢠Earnings Beat ⢠Raised Guidance ⢠Valuation Risk Envista's earnings beat, raised guidance, and growing institutional support strengthen its outlook, though elevated valuation and China/tariff risks warrant caution.
AI Summary
NVST's investment case now hinges on Investor Day validating sustained 3.5%â4.5% organic growth and durable margin expansion, which could justify a re-rating, but at ~12x EV/EBITDA and elevated earnings multiples, any evidence that Q2's recovery was temporaryâespecially amid China pricing and cost pressuresâwould leave limited downside protection.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |